Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nephrotic Syndrome | 6 | 2023 | 25 | 2.810 |
Why?
|
| Podocytes | 7 | 2023 | 41 | 2.550 |
Why?
|
| Kidney Glomerulus | 8 | 2016 | 47 | 1.900 |
Why?
|
| Common Cold | 2 | 2023 | 6 | 1.740 |
Why?
|
| Proteinuria | 7 | 2023 | 57 | 1.720 |
Why?
|
| Angiopoietins | 7 | 2016 | 15 | 1.640 |
Why?
|
| Transcription Factors | 5 | 2023 | 159 | 1.560 |
Why?
|
| Kidney | 16 | 2012 | 155 | 1.390 |
Why?
|
| Homeodomain Proteins | 4 | 2023 | 58 | 1.360 |
Why?
|
| Nephrosis, Lipoid | 2 | 2023 | 10 | 1.260 |
Why?
|
| Animals | 28 | 2023 | 3386 | 1.090 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 2 | 2019 | 34 | 1.030 |
Why?
|
| Hypertriglyceridemia | 2 | 2014 | 13 | 0.910 |
Why?
|
| Mice | 18 | 2023 | 1280 | 0.910 |
Why?
|
| Kidney Diseases | 5 | 2014 | 99 | 0.850 |
Why?
|
| AIDS-Associated Nephropathy | 2 | 2012 | 7 | 0.760 |
Why?
|
| Disease Models, Animal | 4 | 2011 | 568 | 0.740 |
Why?
|
| Gene Expression Regulation | 2 | 2007 | 236 | 0.500 |
Why?
|
| Proteins | 3 | 2003 | 54 | 0.480 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2016 | 87 | 0.470 |
Why?
|
| Rats | 7 | 2013 | 598 | 0.470 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 14 | 0.460 |
Why?
|
| Feedback, Physiological | 1 | 2013 | 10 | 0.450 |
Why?
|
| Membrane Proteins | 4 | 2012 | 151 | 0.440 |
Why?
|
| Humans | 22 | 2023 | 25965 | 0.430 |
Why?
|
| Telomerase | 1 | 2012 | 9 | 0.390 |
Why?
|
| Wnt Signaling Pathway | 1 | 2012 | 31 | 0.380 |
Why?
|
| Diabetic Nephropathies | 6 | 2008 | 22 | 0.310 |
Why?
|
| Albuminuria | 2 | 2023 | 14 | 0.310 |
Why?
|
| Chimera | 1 | 2007 | 3 | 0.290 |
Why?
|
| Animals, Genetically Modified | 1 | 2007 | 17 | 0.290 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 91 | 0.280 |
Why?
|
| Fetal Diseases | 1 | 2003 | 3 | 0.220 |
Why?
|
| Glucose | 5 | 2008 | 48 | 0.220 |
Why?
|
| Glomerular Basement Membrane | 1 | 2023 | 3 | 0.220 |
Why?
|
| Recurrence | 1 | 2023 | 306 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 185 | 0.200 |
Why?
|
| Rats, Transgenic | 2 | 2011 | 18 | 0.190 |
Why?
|
| Recombinant Proteins | 3 | 2014 | 199 | 0.180 |
Why?
|
| Gene Expression Regulation, Developmental | 4 | 2005 | 28 | 0.180 |
Why?
|
| Kidney Tubules | 3 | 2012 | 7 | 0.170 |
Why?
|
| Genes, Homeobox | 1 | 2019 | 5 | 0.170 |
Why?
|
| Zinc Fingers | 1 | 2019 | 12 | 0.170 |
Why?
|
| RNA, Messenger | 6 | 2012 | 264 | 0.160 |
Why?
|
| Glomerulonephritis | 2 | 2010 | 20 | 0.150 |
Why?
|
| Molecular Sequence Data | 4 | 2006 | 162 | 0.150 |
Why?
|
| rap GTP-Binding Proteins | 3 | 2008 | 3 | 0.140 |
Why?
|
| Mice, Knockout | 2 | 2010 | 265 | 0.140 |
Why?
|
| Oxidoreductases | 2 | 2005 | 9 | 0.130 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2006 | 317 | 0.130 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2005 | 29 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 2 | 2007 | 51 | 0.120 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2014 | 3 | 0.120 |
Why?
|
| Drug Design | 1 | 2014 | 22 | 0.120 |
Why?
|
| Pregnancy | 6 | 2005 | 305 | 0.110 |
Why?
|
| Receptors, Vitronectin | 1 | 2013 | 5 | 0.110 |
Why?
|
| Rats, Zucker | 1 | 2013 | 7 | 0.110 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2013 | 4 | 0.110 |
Why?
|
| Autoantibodies | 2 | 2014 | 71 | 0.110 |
Why?
|
| Serum Albumin | 1 | 2013 | 21 | 0.110 |
Why?
|
| Cadherins | 2 | 2003 | 34 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2013 | 61 | 0.110 |
Why?
|
| Immunohistochemistry | 2 | 2003 | 335 | 0.100 |
Why?
|
| Lipoprotein Lipase | 1 | 2012 | 1 | 0.100 |
Why?
|
| Triglycerides | 1 | 2012 | 40 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2003 | 485 | 0.100 |
Why?
|
| Cisplatin | 1 | 2012 | 47 | 0.100 |
Why?
|
| DNA Primers | 3 | 2006 | 45 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2012 | 40 | 0.100 |
Why?
|
| Prednisone | 1 | 2011 | 61 | 0.090 |
Why?
|
| Blotting, Western | 3 | 2012 | 133 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2005 | 119 | 0.090 |
Why?
|
| Glucocorticoids | 1 | 2011 | 62 | 0.090 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2008 | 19 | 0.090 |
Why?
|
| Focal Infection | 1 | 2010 | 1 | 0.090 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2010 | 9 | 0.090 |
Why?
|
| Muscle, Skeletal | 1 | 2013 | 358 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 176 | 0.090 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2010 | 22 | 0.090 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 200 | 0.090 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2006 | 7 | 0.080 |
Why?
|
| HIV-1 | 1 | 2011 | 223 | 0.080 |
Why?
|
| Mitochondria | 1 | 2008 | 57 | 0.080 |
Why?
|
| Hyperglycemia | 2 | 2005 | 28 | 0.080 |
Why?
|
| Mice, Inbred ICR | 5 | 2008 | 12 | 0.070 |
Why?
|
| Pregnancy in Diabetics | 2 | 2005 | 3 | 0.070 |
Why?
|
| Cell Membrane Permeability | 1 | 2007 | 54 | 0.070 |
Why?
|
| Proteoglycans | 1 | 2007 | 128 | 0.070 |
Why?
|
| Cathepsin L | 1 | 2006 | 2 | 0.070 |
Why?
|
| Cathepsin B | 1 | 2006 | 5 | 0.070 |
Why?
|
| Cysteine Endopeptidases | 1 | 2006 | 5 | 0.070 |
Why?
|
| Cathepsins | 1 | 2006 | 4 | 0.070 |
Why?
|
| Oxidative Stress | 2 | 2005 | 96 | 0.070 |
Why?
|
| Protein Kinase C | 2 | 2008 | 47 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2006 | 25 | 0.070 |
Why?
|
| Blood Glucose | 2 | 2005 | 99 | 0.070 |
Why?
|
| DNA, Complementary | 2 | 2003 | 23 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 2 | 2003 | 73 | 0.070 |
Why?
|
| Amino Acid Sequence | 2 | 2003 | 132 | 0.070 |
Why?
|
| Inositol Oxygenase | 1 | 2005 | 1 | 0.070 |
Why?
|
| Water-Electrolyte Balance | 1 | 2005 | 4 | 0.070 |
Why?
|
| Male | 7 | 2012 | 13981 | 0.060 |
Why?
|
| HIV Infections | 1 | 2011 | 463 | 0.060 |
Why?
|
| Young Adult | 1 | 2011 | 1848 | 0.060 |
Why?
|
| Amyloidosis | 1 | 2005 | 26 | 0.060 |
Why?
|
| Aldehyde Reductase | 2 | 2002 | 2 | 0.060 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 47 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2004 | 19 | 0.060 |
Why?
|
| Pregnancy, Animal | 1 | 2003 | 1 | 0.060 |
Why?
|
| Embryonic and Fetal Development | 1 | 2003 | 5 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 37 | 0.060 |
Why?
|
| Rodentia | 1 | 2003 | 5 | 0.060 |
Why?
|
| Molecular Structure | 1 | 2003 | 15 | 0.060 |
Why?
|
| Molecular Biology | 1 | 2003 | 11 | 0.060 |
Why?
|
| Dinoprostone | 1 | 2003 | 15 | 0.060 |
Why?
|
| Extracellular Matrix | 1 | 2004 | 47 | 0.060 |
Why?
|
| Arachidonic Acid | 1 | 2003 | 12 | 0.060 |
Why?
|
| Congenital Abnormalities | 1 | 2003 | 10 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2003 | 45 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2003 | 10 | 0.050 |
Why?
|
| Densitometry | 1 | 2003 | 8 | 0.050 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2003 | 16 | 0.050 |
Why?
|
| Dimerization | 1 | 2003 | 15 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 22 | 0.050 |
Why?
|
| Protein Binding | 1 | 2003 | 113 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2003 | 25 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2003 | 30 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2003 | 26 | 0.050 |
Why?
|
| Forecasting | 1 | 2003 | 91 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 96 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2005 | 173 | 0.050 |
Why?
|
| Animals, Newborn | 4 | 2005 | 38 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2011 | 3292 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2002 | 6 | 0.050 |
Why?
|
| Fibronectins | 1 | 2002 | 21 | 0.050 |
Why?
|
| Nephrons | 1 | 2002 | 5 | 0.050 |
Why?
|
| Mesoderm | 1 | 2002 | 19 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2002 | 19 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2003 | 621 | 0.050 |
Why?
|
| Female | 7 | 2005 | 14348 | 0.040 |
Why?
|
| Apoptosis | 3 | 2008 | 193 | 0.040 |
Why?
|
| Time Factors | 1 | 2003 | 1361 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2012 | 475 | 0.040 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2008 | 14 | 0.030 |
Why?
|
| Blotting, Northern | 2 | 2005 | 20 | 0.030 |
Why?
|
| Transfection | 2 | 2005 | 104 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2014 | 25 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2014 | 39 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2014 | 60 | 0.030 |
Why?
|
| Receptors, Lipoprotein | 1 | 2012 | 1 | 0.030 |
Why?
|
| Adipose Tissue, White | 1 | 2012 | 2 | 0.030 |
Why?
|
| Azo Compounds | 1 | 2012 | 3 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2012 | 3 | 0.030 |
Why?
|
| Coloring Agents | 1 | 2012 | 12 | 0.030 |
Why?
|
| Necrosis | 1 | 2012 | 26 | 0.030 |
Why?
|
| Neutrophil Infiltration | 1 | 2012 | 9 | 0.030 |
Why?
|
| In Situ Hybridization | 2 | 2002 | 40 | 0.030 |
Why?
|
| Body Weight | 1 | 2012 | 121 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2012 | 124 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 179 | 0.020 |
Why?
|
| Liver | 1 | 2012 | 123 | 0.020 |
Why?
|
| Silicon Dioxide | 1 | 2010 | 1 | 0.020 |
Why?
|
| Peroxidase | 1 | 2010 | 16 | 0.020 |
Why?
|
| Peptide Hydrolases | 1 | 2010 | 9 | 0.020 |
Why?
|
| Vasculitis | 1 | 2010 | 26 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2010 | 100 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2008 | 11 | 0.020 |
Why?
|
| DNA, Mitochondrial | 1 | 2008 | 8 | 0.020 |
Why?
|
| Sepsis | 1 | 2010 | 137 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2008 | 13 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 20 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2008 | 10 | 0.020 |
Why?
|
| Glycation End Products, Advanced | 1 | 2008 | 7 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2008 | 13 | 0.020 |
Why?
|
| Cell Line | 1 | 2008 | 244 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 103 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2008 | 111 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 92 | 0.020 |
Why?
|
| Sorbitol | 1 | 2005 | 1 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 14 | 0.020 |
Why?
|
| Inositol | 1 | 2005 | 6 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2005 | 19 | 0.020 |
Why?
|
| Response Elements | 1 | 2005 | 13 | 0.020 |
Why?
|
| Luciferases | 1 | 2005 | 22 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2005 | 25 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2005 | 43 | 0.020 |
Why?
|
| Hypertension | 1 | 2008 | 217 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2008 | 388 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2005 | 65 | 0.020 |
Why?
|
| Embryonic Development | 1 | 2005 | 3 | 0.020 |
Why?
|
| Disease Progression | 1 | 2008 | 685 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2005 | 56 | 0.020 |
Why?
|
| Biopsy | 1 | 2005 | 199 | 0.020 |
Why?
|
| Mammals | 1 | 2004 | 22 | 0.010 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2002 | 7 | 0.010 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2002 | 6 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2002 | 20 | 0.010 |
Why?
|
| Streptozocin | 1 | 2002 | 2 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2002 | 4 | 0.010 |
Why?
|
| Wheat Germ Agglutinins | 1 | 2002 | 1 | 0.010 |
Why?
|
| Antisense Elements (Genetics) | 1 | 2002 | 2 | 0.010 |
Why?
|
| Autoradiography | 1 | 2002 | 6 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2005 | 250 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 89 | 0.010 |
Why?
|
| DNA | 1 | 2002 | 93 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2002 | 73 | 0.010 |
Why?
|
| Aldo-Keto Reductases | 1 | 2002 | 1 | 0.010 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2002 | 1 | 0.010 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2002 | 1 | 0.010 |
Why?
|
| Gestational Age | 1 | 2002 | 68 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 104 | 0.010 |
Why?
|
| Ubiquitin | 1 | 2002 | 24 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2002 | 79 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2002 | 119 | 0.010 |
Why?
|
| Adult | 1 | 2010 | 7349 | 0.010 |
Why?
|
| Middle Aged | 1 | 2005 | 8508 | 0.010 |
Why?
|